2023-10-12 08:45
Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida.
2023-09-28 10:30
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024. The gap-fill process is an established...
2023-09-25 08:00
Biovica, active in cancer monitoring, today announces that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population.
2023-09-19 09:00
Biovica today announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTum® TKa for patients...
2023-09-06 08:00
Higher sales and commercial milestones achieved in the USA
2023-09-05 13:00
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 5 September 2023 and the following resolutions were passed by the meeting.
2023-08-24 10:30
Biovica, active in cancer diagnostics, today announces the initiation of a prospective clinical trial to study the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients...
2023-08-04 12:30
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 5 September 2023, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds Väg 38 in...
2023-07-31 08:00
Biovica today announces that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners.
2023-07-21 08:00
Biovica, active in cancer monitoring, today announces that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States.
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects